520,000 Shares in BioCryst Pharmaceuticals, Inc. $BCRX Bought by Elmind Capital LP

Elmind Capital LP purchased a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 520,000 shares of the biotechnology company's stock, valued at approximately $5,200,000. BioCryst Pharmaceuticals accounts for 0.0% of Elmind Capital LP's investment portfolio, making the stock its 19th biggest position. Elmind Capital LP owned 0.20% of BioCryst Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the business. ADAR1 Capital Management LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter valued at $1,330,000. Hsbc Holdings PLC purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter worth $1,079,000. PDT Partners LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth $245,000. Canada Pension Plan Investment Board purchased a new position in shares of BioCryst Pharmaceuticals in the second quarter valued at approximately $1,158,000. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of BioCryst Pharmaceuticals during the second quarter worth about $16,243,000. 85.88% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Needham & Company LLC cut their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Wednesday, May 6th. Cantor Fitzgerald raised their target price on shares of BioCryst Pharmaceuticals from $27.00 to $29.00 and gave the company an "overweight" rating in a research report on Tuesday, June 30th. Wedbush dropped their target price on shares of BioCryst Pharmaceuticals from $21.00 to $20.00 and set an "outperform" rating on the stock in a research report on Thursday, August 6th. Royal Bank Of Canada lowered their price objective on BioCryst Pharmaceuticals from $14.00 to $13.00 and set an "outperform" rating for the company in a research report on Thursday, August 6th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $32.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, June 30th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $20.60.

BioCryst Pharmaceuticals Stock Performance

BCRX stock traded down $0.03 during mid-day trading on Friday, hitting $9.84. 1,813,531 shares of the company were exchanged, compared to its average volume of 4,808,115. The firm's 50 day simple moving average is $9.70 and its 200 day simple moving average is $9.05. The firm has a market cap of $2.51 billion, a P/E ratio of -6.56 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $0.30 earnings per share for the quarter, topping analysts' consensus estimates of $0.15 by $0.15. The business had revenue of $218.25 million during the quarter, compared to the consensus estimate of $183.28 million. BioCryst Pharmaceuticals had a negative net margin of 40.90% and a negative return on equity of 86.89%. BioCryst Pharmaceuticals's quarterly revenue was up 33.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.15 earnings per share. On average, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -2.25 EPS for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company's first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.